A TaqMan low-density array to predict outcome in advanced hodgkin's Lymphoma using paraffin-embedded samples

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1367-1375

  Sánchez Espiridión, Beatriz ^a   Sánchez Aguilera, Abel ^a   Montalbán, Carlos ^c   Martin, Carmen ^d   Martinez, Rafael ^d   González Carrero, Joaquin ^g   Poderos, Concepción ^g   Bellas, Carmen ^c   Fresno, Manuel F ^g   Morante, Cesar ^h   Mestre, Maria J ^e   Mendez, Miguel ^e   Mazorra, Francisco ⁱ   Conde, Eulogio ⁱ   Castaño, Angel ^f   Sánchez Godoy, Pedro ^f   Tomas, José F ^b   Morente, Manolo M ^a   Piris, Miguel A ^a   Garcfa, Juan F ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b MD ANDERSON CANCER CENTER   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL DE MÓSTOLES   (Spain)

^f HOSPITAL SEVERO OCHOA   (Spain)

^g Hospital Severo Ochoa de Leganes ^*  (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HISTONE; PARAFFIN;

ARTICLE; CANCER PATIENT; CELL POPULATION; CLINICAL ARTICLE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN MODIFICATION; REED STERNBERG CELL; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; FEMALE; GENETICS; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; FEMALE; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 63149134916     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1119     Document Type: Article

References (56)

1. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443-50.
2. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A1994;91:10962-6.
3. Kanzler H, Hansmann ML, Kapp U, et al. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient Blood 1996;87:3429-36.
4. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-97.
5. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002;13 Suppl 1:52-6.
6. Van den Berg A, Visser L, Poppema S. High expression of the CC chemokineTARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685-91.
7. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346: 1417-8.
8. Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P. Survival in Hodgkin's disease patients- report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005;41:998-1006.
9. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005;23: 6400-8. 10. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 1998;339:1506-14.
10. Gobbi PG, Zinzani PL, Broglia C, et al. Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer 2001;91:1467-78.
11. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100:3935-41.
12. Rassidakis GZ, Medeiros LJ, McDonnell TJ, et al. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin Cancer Res 2002;8:488-93.
13. Garcia JF, Camacho Fl, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;101:681-9.
14. Herling M, Rassidakis GZ, Vassilakopoulos TP, Medeiros LJ, Sarris AH. Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma. Blood 2006;107:1240; author reply 1241.
15. Montalban C, Garcia JF, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22:1664-73.
16. Juszczynski P, OuyangJ, Monti S, et al. The API-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2007;104: 13134-9.
17. IshidaT, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006;66:5716-22.
18. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatoryTcells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103:1755-62.
19. Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 2005;23: 6379-86.
20. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxicTcells as prognostic marker in Hodgkin's disease. Blood 1997;89:1376-82.
21. Ten Berge RL, Oudejans JJ, Dukers DF, MeijerJW, Ossenkoppele GJ, Meijer CJ. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia 2001;15: 458-64.
22. Alvaro T Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467 - 73.
23. Sanchez-Aguilera A, Montalban C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662-8.
24. Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002;13 Suppl 1:86-91.
25. Montaner D,Tarraga J, Huerta-Cepas J, et al. Next station in microarray data analysis: GEPAS. Nucleic Acids Res 2006;34:W486-91.
26. Green GH, Diggle PJ. On the operational characteristics of the Benjamini and Hochberg false discovery rate procedure. Stat Appl Genet Mol Biol 2007; 6:Article27.
27. Subramanian A.Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
28. Koch I, Slotta-Huspenina J, Hollweck R, et al. Real-time quantitative RT-PCR shows variable, assay-dependent sensitivity to formalin fixation: implications for direct comparison of transcript levels in paraffin-embedded tissues. Diagn Mol Pathol 2006;15:149-56.
29. Bonanomi A, Kojic D, Giger B, et al. Quantitative cytokine gene expression in human tonsils at excision and during histoculture assessed by standardized and calibrated real-time PCR and novel data processing. J Immunol Methods 2003;283:27-43.
30. Ohl F, Jung M, Radonic A, Sachs M, Loening SA, Jung K. Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J Urol 2006;175: 1915-20.
31. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RE- SEARCH0034.
32. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561 -77.
33. Navarro A, Gaya A, Martinez A, et al. MicroRNA expression profiling in classical Hodgkin lymphoma. Blood 2008;111:2825-32.
34. Kuppers R, Klein U, Schwering I, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 2003;111: 529-37.
35. Fiumara P, Snell V. Li Y, et al. Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines. Blood 2001;98:2784-90.
36. Oelmann E, Herbst H, Zuhlsdorf M, et al. Tissue inhibitor of met alloproteinases 1 is an autocrine and paracrine survival factor, with additional immune- regulatory functions, expressed by Hodgkin/Reed- Sternberg cells. Blood 2002;99:258-67.
37. Manoli T, Gretz N, Grone HJ, Kenzelmann M, Eils R, Brors B. Group testing for pathway analysis improves comparability of different microarray datasets. Bioin- formatics 2006;22:2500-6.
38. Van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24: 4135-42.
39. Gillis AJ, Stoop H J, Hersmus R, et al. High-throughput microRNAome analysis in human germ cell tumours. J Pathol 2007;213:319-28.
40. Devilard E, Bertucci F.Trempat P, et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002;21:3095-102.
41. HagemannT, BozanovicT, Hooper S, et al. Molecular profiling of cervical cancer progression. Br J Cancer 2007:96:321 -8.
42. Glenn ST, Jones CA, Liang P, Kaushik D, Gross KW, Kim HL. Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. Biotechniques 2007;43:639-40, 642- 633, 647.
43. Noutsias M, Rohde M, Block A, et al. Preampli- fication techniques for real-time RT-PCR analyses of endomyocardial biopsies. BMC Mol Biol 2008; 9:3.
44. Morente MM, Piris MA, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 1997;90:2429-36.
45. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12.
46. Duxbury MS, Ito H, Zinner MJ. Ashley SW, Whang EE. RNA interference targeting the M2subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004;23:1539-48.
47. Hilliker C, Delabie J, Speleman F, et al. Localization of the gene (RSN) coding for restin, a marker for Reed-Sternberg cells in Hodgkin's disease, to human chromosome band 12q24.3 and YAC cloning of the locus. Cytogenet Cell Genet 1994;65:172-6.
48. Slep KC,Vale RD. Structural basis of microtubule plus end tracking by XMAP215, CLIP-170, and EB1. Mol Cell 2007;27:976 - 91.
49. Wang TL, Diaz LA, Jr., Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA2004;101:3089-94.
50. Farrugia DC, Ford HE, Cunningham D, et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 2003;9:792-801.
51. Kamal A, Boehm MR Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004;10:283-90.
52. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 2000;97:10832-7.
53. Broemer M, Krappmann D, Scheidereit C. Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene 2004,23:5378-86.
54. Georgakis GV, Li Y, Rassidakis GZ, Martinez- Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17- demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;12:584-90.
55. Alvaro T, Lejeune M, Camacho Fl, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006:91: 1605-12.
56. Dave SS,Wright G,Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-69.